<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118984</url>
  </required_header>
  <id_info>
    <org_study_id>Azithromycin in MSAF cases</org_study_id>
    <nct_id>NCT05118984</nct_id>
  </id_info>
  <brief_title>Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes</brief_title>
  <official_title>Comparison Between Azithromycin vs Placebo in Cases of Meconium Stained Amniotic Fluid During the First Stage of Labor in Multigravida Women and Their Effect on Maternal and Neonatal Outcomes, a Double-blind, Placebo-controlled Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meconium stained amniotic fluid increases the risk of maternal complications (e.g., dystocia,&#xD;
      operative delivery, and postpartum endometritis) and neonatal complications (e.g., sepsis,&#xD;
      admission to the neonatal intensive care unit [NICU], and meconium aspiration syndrome). The&#xD;
      goal of the study is to compare between Azithromycin vs Placebo in cases of meconium stained&#xD;
      amniotic fluid during the first stage of labor in multigravida women and their effect on&#xD;
      maternal and neonatal outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meconium stained amniotic fluid, a troublesome situation both for obstetrician and&#xD;
      pediatrician, it is associated with high rates of caesarean section, perinatal morbidity and&#xD;
      mortality. The rate of meconium-stained amniotic fluid varies from 12 to 20%.It is higher in&#xD;
      underdeveloped countries.Our study design would be a prospective randomized trial. Consented,&#xD;
      eligible pregnant women presenting during the first stage of labor at or more than 37 weeks&#xD;
      of gestation with meconium stained amniotic fluid will be randomized to receive Azithromycin&#xD;
      capsule (Zithromax, Pfizer) (250 mg / 12hrs on empty stomach for 3 days)(Group 1).Group 2&#xD;
      will be offered placebo capsules (manufactured in pharmacy department with the same shape,&#xD;
      color and consistency as Azithromycin capsule for 3 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Actual">October 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible participant will be allocated to one of two groups :&#xD;
Group 1 will be offered Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).&#xD;
Group 2 will be offered placebo capsules (manufactured in pharmacy department with the same shape, colour and consistency as Azithromycin capsule for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patients will be randomized to the 2 study groups according to a 2-block randomization list coded I or II at a 1:1 ratio. The randomization list will be prepared using a computer- generated random table by a statistician not otherwise involved in the study. The allocated groups will be masked in serially numbered sealed opaque envelopes that will be opened only after enrollment. Women who will be recruited give consent and open randomization envelopes in early labor, also the women will be recruited before revealing the allocation, the allocation will be blind to both the recruiter and the participant.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Azithromycin vs Placebo in cases of meconium stained amniotic fluid during the first stage of labor in multigravida women and their effect on occurrence of maternal fever, postpartum endometritis and skin (episiotomy/tear) infection.</measure>
    <time_frame>within 1 week from delivery</time_frame>
    <description>Mothers will be followed up during her stay in the postnatal ward regarding signs of infection (fever, maternal tachycardia, offensive vaginal discharge, uterine tenderness). Postpartum follow up visit 1 week after delivery will be conducted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Azithromycin vs Placebo in cases of meconium stained amniotic fluid during the first stage of labor in multigravida women and their effect on occurrence of neonatal fever , pneumonia and skin infection .</measure>
    <time_frame>within 1 week from delivery</time_frame>
    <description>Neonates were followed up for incidence of neonatal pneumonia, neonatal skin infection , neonatal fever.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal necessity for NICU admission and/or mechanical ventilation.</measure>
    <time_frame>after delivery and within 1 week postartum</time_frame>
    <description>Incidence of NICU admission and/or mechanical ventilation in neonates born to women with MSAF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of meconium aspiration</measure>
    <time_frame>after delivery and within 1 week postpartum</time_frame>
    <description>Neonates will be followed up for presence or absence of meconium aspiration, APGAR score at 1 and 5 minutes, RDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2- Side effects of drug (diarrhea, stomach cramps, vomiting, allergy and anaphylactic shock).</measure>
    <time_frame>wwithin 1 week postpartum</time_frame>
    <description>Mothers follow up for incidence of side effects related to Azithromycin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Meconium Stained</condition>
  <condition>Azithromycin</condition>
  <condition>Postpartum Endometritis</condition>
  <arm_group>
    <arm_group_label>Azithromycin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule every 12hrs for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin capsule (Zithromax, Pfizer) (250 mg)</intervention_name>
    <description>Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.</description>
    <arm_group_label>Azithromycin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A treatment that has no active properties</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Multigravida pregnant women with meconium stained amniotic fluid encountered either by&#xD;
             spontaneous/artificial amniotomy during the first stage of labor in the ward provided&#xD;
             that the gestational age at delivery is 37 weeks of gestation or more.&#xD;
&#xD;
          2. Singleton living gestation&#xD;
&#xD;
          3. Cephalic presentation&#xD;
&#xD;
          4. Adequate pelvis&#xD;
&#xD;
          5. An informed written consent for the proposed study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primigravids&#xD;
&#xD;
          2. Women with previous cesarean section&#xD;
&#xD;
          3. Multifetal gestation&#xD;
&#xD;
          4. Intrauterine fetal death&#xD;
&#xD;
          5. Malpresentations&#xD;
&#xD;
          6. Prematurity (&lt;37 weeks )&#xD;
&#xD;
          7. Abnormally invasive placenta during the current pregnancy&#xD;
&#xD;
          8. Medical disorders with pregnancy&#xD;
&#xD;
          9. Contracted pelvis&#xD;
&#xD;
         10. Evidence of maternal infection&#xD;
&#xD;
         11. Allergy to azithromycin or other macrolides that is self-reported or documented in the&#xD;
             medical record.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gamal GamalEldin Youssef, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman Aly Hussein Aly, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Samir Rashwan, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Giza</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://emedicine.medscape.com/article/261137-overview#a2</url>
    <description>Premature Rupture of Membranes: Overview, Premature Rupture of Membranes (at Term), Premature Preterm Rupture of Membranes. Medscape.</description>
  </link>
  <link>
    <url>http://doi.org/10.4038/sljog.v42i1.7927</url>
    <description>Antibiotics for women with prelabour rupture of membranes at term, undergoing induction of labour after 12 hours - A randomized controlled trial. Sri Lanka Journal of Obstetrics and Gynaecology, 42(1), 12-20.</description>
  </link>
  <link>
    <url>http://doi.org/10.1891/0730-0832.37.3.141</url>
    <description>Management of meconium-stained newborns in the delivery room.</description>
  </link>
  <link>
    <url>http://doi.org/10.1016/j.clp.2005.04.005</url>
    <description>Postpartum endometritis</description>
  </link>
  <link>
    <url>http://www.bellybelly.com.au/birth/what-is-the-real-risk-of-infection-after-waters-break/</url>
    <description>What Is The Real Risk Of Infection After Waters Break?</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/abs/pii/B9780128001738000015</url>
    <description>Azithromycin</description>
  </link>
  <link>
    <url>http://doi.org/10.1155/2018/7162478</url>
    <description>A Retrospective Study on the Risk of Respiratory Distress Syndrome in Singleton Pregnancies with Preterm Premature Rupture of Membranes between 24+0 and 36+6 Weeks, Using Regression Analysis for Various Factors</description>
  </link>
  <link>
    <url>http://doi.org/10.1097/AOG.0000000000001712</url>
    <description>â€¢ American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics (2016). Practice Bulletin No. 172: Premature Rupture of Membranes.</description>
  </link>
  <link>
    <url>http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6823264&amp;blobtype=pdf</url>
    <description>Antibiotics for meconium-stained amniotic fluid in labour for preventing maternal and neonatal infections</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Kamal Zaghloul</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Azithromycin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Postpartum Endometritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

